Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comment on: Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease

Comment on: Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial... American Journal of Cardiovascular Drugs (2020) 20:505 https://doi.org/10.1007/s40256-020-00412-2 LE T TER TO  THE   EDITOR Comment on: Non‑vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease 1 2 2 3 Igor Vaz  · Ashish Kumar  · Mariam Shariff  · Rajkumar Doshi Published online: 11 August 2020 © Springer Nature Switzerland AG 2020 Sir, NOACs were noninferior to warfarin in patients with atrial fibrillation and liver disease, but the present meta-analysis We read with interest the systemic review and meta-analysis did not define a noninferiority margin. by Fu et al. [1] published in the American Journal of Car- diovascular Drugs. We have the following concerns. From the meta-analysis, the authors concluded that non-vitamin Compliance with Ethical Standards K antagonist oral anticoagulants (NOACs) were associated Conflict of Interest Igor Vaz, Ashish Kumar, Mariam Shariff, and Ra- with a lower risk of all-cause mortality and major bleed- jkumar Doshi have no potential conflicts of interest that might be rel- ing than warfarin in patients with atrial fibrillation and liver evant to this Letter to the Editor. disease. However, as interpreted with Higgins I statistics, these pooled estimates were associated with considerable heterogeneity. This could be because of the difference in the References severity of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Comment on: Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease

Comment on: Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease

Abstract

American Journal of Cardiovascular Drugs (2020) 20:505 https://doi.org/10.1007/s40256-020-00412-2 LE T TER TO  THE   EDITOR Comment on: Non‑vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease 1 2 2 3 Igor Vaz  · Ashish Kumar  · Mariam Shariff  · Rajkumar Doshi Published online: 11 August 2020 © Springer Nature Switzerland AG 2020 Sir, NOACs...
Loading next page...
 
/lp/springer-journals/comment-on-non-vitamin-k-antagonist-oral-anticoagulants-versus-E5gWU1kUD0

References (2)

Publisher
Springer Journals
Copyright
Copyright © Springer Nature Switzerland AG 2020
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-020-00412-2
Publisher site
See Article on Publisher Site

Abstract

American Journal of Cardiovascular Drugs (2020) 20:505 https://doi.org/10.1007/s40256-020-00412-2 LE T TER TO  THE   EDITOR Comment on: Non‑vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease 1 2 2 3 Igor Vaz  · Ashish Kumar  · Mariam Shariff  · Rajkumar Doshi Published online: 11 August 2020 © Springer Nature Switzerland AG 2020 Sir, NOACs were noninferior to warfarin in patients with atrial fibrillation and liver disease, but the present meta-analysis We read with interest the systemic review and meta-analysis did not define a noninferiority margin. by Fu et al. [1] published in the American Journal of Car- diovascular Drugs. We have the following concerns. From the meta-analysis, the authors concluded that non-vitamin Compliance with Ethical Standards K antagonist oral anticoagulants (NOACs) were associated Conflict of Interest Igor Vaz, Ashish Kumar, Mariam Shariff, and Ra- with a lower risk of all-cause mortality and major bleed- jkumar Doshi have no potential conflicts of interest that might be rel- ing than warfarin in patients with atrial fibrillation and liver evant to this Letter to the Editor. disease. However, as interpreted with Higgins I statistics, these pooled estimates were associated with considerable heterogeneity. This could be because of the difference in the References severity of

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Oct 11, 2020

There are no references for this article.